Changes in kidney function, promoting sodium and fluid retention
- Oral semaglutide (only FDA approved for diabetes treatment) and injectable liraglutide, (FDA approved for obesity treatment as Saxenda,) lead to relatively modest amount of weight loss
A New Era in Medical Weight Management Inspired by growing consumer interest in GLP-1s, medications like tirzepatide and semaglutide represent a more effective approach to health management
Billing disputes, difficulty canceling, and unresponsive customer service appear most frequently
Trying to pick the right weight loss service or weight loss medications these days honestly feels like scrolling through Netflix
In a randomized, placebo-controlled study, pemvidutide, a dual GLP-1/GCG receptor agonist, significantly decreased liver fat content by up to 68.5% after 12 weeks of treatment, accompanied by reductions in hepatic inflammation markers and body weight, highlighting the potential of dual receptor agonists to modify MASLD pathophysiology (47)